At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,104 enrolled
Drug / intervention
MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeksdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled "Factorial" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet in Patients With Primary Hypercholesterolemia
In Brief
A Phase 3 clinical trial evaluating MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks for Hypercholesterolemia. Completed, enrolled 1,104 participants.
Detailed Summary
The purpose of this study is to evaluate the lipid lowering effects of an investigational drug in patients with hypercholesterolemia (high cholesterol).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2003
Primary CompletionSep 2003
First PostedSep 2004
TodayJul 2026
First PostedSep 28, 2004
Enrollment StartJan 1, 2003
Primary CompletionSep 1, 2003
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 21.8 years ago
Interventions
MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeksdrug